Lupin Completes Acquisition of VISUfarma
Mumbai, London, Rome, Zug, April 2, 2026 – Lupin Limited announced the completion of its acquisition of VISUfarma B.V. (VISUfarma) from GHO Capital Partners LLP (GHO). The acquisition expands Lupin's specialty care portfolio and strengthens its presence in Europe.The integration of VISUfarma has expanded Lupin's ophthalmology portfolio to over 60 branded products spanning dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health, and specialty nutraceuticals. VISUfarma has a commercial footprint across key European markets, including Italy, the UK, Spain, Germany, and France.
VISUfarma generated €53 million in revenue in 2025 across Italy, the UK, Spain, Germany, France, and certain international markets.
Vinita Gupta, CEO of Lupin, stated that the acquisition marks an exciting milestone, adding a portfolio of eye health products and expanding the company's presence across Europe.
Paolo Cioccetti, CEO Italy, VISUfarma, said the company is thrilled to partner with Lupin and confident in making a significant impact in advancing eye care across Europe and beyond.
Lupin Limited is a global pharmaceutical company with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupin has 15 manufacturing sites and 7 research centers globally, with a workforce of over 24,000 professionals.
About VISUfarma
Founded in 2016 through the combination of the Italian company Visufarma SpA and the European commercial activities of Nicox SA, VISUfarma is a specialty pharmaceutical company focused on ophthalmology.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.